Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor.
1. The hyperactivity and hyperpyrexia produced by L-tryptophan in rats treated with a monoamine oxidase inhibitor was inhibited by chlorpromazine.2. Chlorpromazine did not inhibit the increased rate of synthesis of brain 5-hydroxytryptamine (5-HT) produced by tryptophan loading.3. Hyperactivity and hyperpyrexia were also produced by 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) in rats. Pretreatment with a monoamine oxidase inhibitor potentiated the hyperactivity response. Pretreatment of rats with p-chlorophenylalanine did not inhibit hyperactivity produced by 5-MeODMT.4. Chlorpromazine inhibits hyperactivity caused by tryptophan or 5-MeODMT after monoamine oxidase inhibition either by competition with 5-HT or 5-MeODMT, respectively, at receptor sites or by physiological antagonism.
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002746:Chlorpromazine / Q000494:pharmacology*; D004357:Drug Synergism; D010134:Fenclonine / Q000494:pharmacology; D005334:Fever / Q000139:chemically induced; D006801:Humans; D006948:Hyperkinesis / Q000139:chemically induced*; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D051381:Rats; D011955:Receptors, Drug; D012701:Serotonin / Q000096:biosynthesis; D014363:Tryptamines / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D014364:Tryptophan / Q000037:antagonists & inhibitors* / Q000494:pharmacology
D008996:Monoamine Oxidase Inhibitors; D011955:Receptors, Drug; D014363:Tryptamines; D012701:Serotonin; D014364:Tryptophan; D010134:Fenclonine; D002746:Chlorpromazine